A global investment framework for the elimination of hepatitis B

JOURNAL OF HEPATOLOGY

卷:74

Article

Howell, Jessica^1,2,3,4  Pedrana, Alisa^1,2  Schroeder, Sophia E.^1,2  Scott, Nick^1,2  Aufegger, Lisa⁵  Atun, Rifat⁶  Baptista-Leite, Ricardo^7,8  Hirnschall, Gottfried^19,20  't Hoen, Ellen^9,10  Hutchinson, Sharon J.^11,12  Lazarus, Jeffrey, V¹³  Olufunmilayo, Lesi¹⁷  Peck, Raquel¹⁴  Sharma, Manik¹⁸  Sohn, Annette H.¹⁵  Thompson, Alexander^3,4  Thursz, Mark¹⁶  Wilson, David^1,2  Hellard, Margaret^1,2,21,22 

[1] Burnet Inst, Dis Eliminat Programme, Melbourne, Vic, Australia

[2] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia

[3] Univ Melbourne, Dept Med, Melbourne, Vic, Australia

[4] St Vincents Hosp, Dept Gastroenterol, Melbourne, Vic, Australia

[5] Imperial Coll London, Ctr Hlth Policy, London, England

[6] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA

[7] Univ Catolica Portuguesa, Lisbon, Portugal

[8] Maastricht Univ, Fac Hlth Med & Life Sci, Maastricht, Netherlands

[9] Univ Med Ctr Groningen, Global Hlth Unit, Groningen, Netherlands

[10] Med Law & Policy, Amsterdam, Netherlands

[11] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland

[12] Hlth Protect Scotland, Cadogan St, Glasgow, Lanark, Scotland

[13] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain

[14] World Hepatitis Alliance, London, England

[15] Fdn AIDS Res, TREAT Asia AmfAR, Bangkok, Thailand

[16] Imperial Coll London, Dept Hepatol, London, England

[17] Univ Lagos, Coll Med, Dept Med, Med, Lagos, Nigeria

[18] Hamad Med Corp, Div Gastroenterol & Hepatol, Hamad Gen Hosp, Doha, Qatar

[19] WHO, Global Hepatitis Programme, Strateg Informat, Melbourne, Vic, Australia

[20] WHO, Dept HIV & Global Hepatitis Programme, Melbourne, Vic, Australia

[21] The Alfred, Dept Infect Dis, Clayton, Vic, Australia

[22] Monash Univ, Clayton, Vic, Australia

关键词: Viral hepatitis;    Hepatitis B;    Disease elimination;    Health financing;    Cost-effectiveness;    alcohol rates;    Universal health coverage;   

DOI  :  10.1016/j.jhep.2020.09.013

来源: Elsevier

【 摘 要 】

Background & Aims: More than 292 million people are living with hepatitis B worldwide and are at risk of death from cirrhosis and liver cancer. The World Health Organization (WHO) has set global targets for the elimination of viral hepatitis as a public health threat by 2030. However, current levels of global investment in viral hepatitis elimination programmes are insufficient to achieve these goals. Methods: To catalyse political commitment and to encourage domestic and international financing, we used published modelling data and key stakeholder interviews to develop an investment framework to demonstrate the return on investment for viral hepatitis elimination. Results: The framework utilises a public health approach to identify evidence-based national activities that reduce viral hepatitis-related morbidity and mortality, as well as international activities and critical enablers that allow countries to achieve maximum impact on health outcomes from their investments - in the context of the WHO's 2030 viral elimination targets. Conclusion: Focusing on hepatitis B, this health policy paper employs the investment framework to estimate the substantial economic benefits of investing in the elimination of hepatitis B and demonstrates how such investments could be cost saving by 2030. Lay summary: Hepatitis B infection is a major cause of death from liver disease and liver cancer globally. To reduce deaths from hepatitis B infection, we need more people to be tested and treated for hepatitis B. In this paper, we outline a framework of activities to reduce hepatitis B-related deaths and discuss ways in which governments could pay for them. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free